Pegoraro 2024 Adv Drug Deliv Rev
| Pegoraro C, Domingo I, Conejos-Sánchez I, Vicent MJ (2024) Unlocking the mitochondria for nanomedicine-based treatments: overcoming biological barriers, improving designs, and selecting verification techniques. |
» Adv Drug Deliv Rev [Epub ahead of print]. PMID: 38325562 Open Access
Pegoraro C, Domingo I, Conejos-Sánchez I, Vicent MJ (2024) Adv Drug Deliv Rev
Abstract: Enhanced targeting approaches will support the treatment of diseases associated with dysfunctional mitochondria, which play critical roles in energy generation and cell survival. Obstacles to mitochondria-specific targeting include the presence of distinct biological barriers and the need to pass through (or avoid) various cell internalization mechanisms. A range of studies have reported the design of mitochondrially-targeted nanomedicines that navigate the complex routes required to influence mitochondrial function; nonetheless, a significant journey lies ahead before mitochondrially-targeted nanomedicines become suitable for clinical use. Moving swiftly forward will require safety studies, in vivo assays confirming effectiveness, and methodologies to validate mitochondria-targeted nanomedicines' subcellular location/activity. From a nanomedicine standpoint, we describe the biological routes involved (from administration to arrival within the mitochondria), the features influencing rational design, and the techniques used to identify/validate successful targeting. Overall, rationally-designed mitochondria-targeted-based nanomedicines hold great promise for precise subcellular therapeutic delivery.
• Bioblast editor: Plangger M
Labels: MiParea: Respiration
HRR: Oxygraph-2k
2024-02
